NLS Pharmaceutics And Kadimastem In Collaboration With ITolerance Announced That Request For Pre-Investigational New Drug Meeting Has Been Submitted To The FDA For ITOL102 For Type 1 Diabetes

Benzinga12/19 20:42

NLS Pharmaceutics Expects to Close Kadimastem Merger by End of January

Yahoo Finance12/12 20:45

Which Subsectors to Own and Which to Avoid – Wolfe Research

Seeking Alpha12/11 02:33

Protara Therapeutic TARA +77% Phase 2 Results; NLS Pharmaceutics NLSP -20% Private Placement

BioPharmCatalyst12/06 13:40

NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market

PR Newswire12/05 02:15

NLS Pharmaceutics Shares Are Trading Higher After the Company Announced Preclinical Data for Its Non-sulfonamide, Dual Orexin Receptor Agonists for Potential Treatment of Narcolepsy and Neurological Disorders.

Benzinga12/03 20:48